BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33288557)

  • 1. Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines.
    Robinson AGJ; Kanaan YM; Copeland RL
    Anticancer Res; 2020 Dec; 40(12):6623-6635. PubMed ID: 33288557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
    Kala R; Shah HN; Martin SL; Tollefsbol TO
    BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological evaluation of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone as an anti-breast cancer agent.
    Kanaan YM; Das JR; Bakare O; Enwerem NM; Berhe S; Beyene D; Williams V; Zhou Y; Copeland RL
    Anticancer Res; 2009 Jan; 29(1):191-9. PubMed ID: 19331150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin suppresses 4-hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway.
    Geng C; Li J; Ding F; Wu G; Yang Q; Sun Y; Zhang Z; Dong T; Tian X
    Biochem Biophys Res Commun; 2016 Apr; 473(1):147-153. PubMed ID: 27012210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology.
    Abuhussein O; Yang J
    Invest New Drugs; 2020 Oct; 38(5):1316-1325. PubMed ID: 32060788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells.
    Jinih M; Wang JH; Pfirrmann RW; O'Leary DP; Corrigan MA; Redmond HP
    Anticancer Res; 2021 May; 41(5):2247-2256. PubMed ID: 33952451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species.
    Roy A; Ahir M; Bhattacharya S; Parida PK; Adhikary A; Jana K; Ray M
    Mol Carcinog; 2017 Sep; 56(9):2086-2103. PubMed ID: 28418078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species.
    Richards CE; Vellanki SH; Smith YE; Hopkins AM
    Cell Oncol (Dordr); 2018 Feb; 41(1):35-46. PubMed ID: 29134467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
    Devulapally R; Sekar TV; Paulmurugan R
    Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells.
    Chisholm K; Bray BJ; Rosengren RJ
    Anticancer Drugs; 2004 Oct; 15(9):889-97. PubMed ID: 15457130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
    Ozawa PMM; Alkhilaiwi F; Cavalli IJ; Malheiros D; de Souza Fonseca Ribeiro EM; Cavalli LR
    Breast Cancer Res Treat; 2018 Dec; 172(3):713-723. PubMed ID: 30173296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KR-33028, a potent inhibitor of the Na
    Amith SR; Wilkinson JM; Fliegel L
    Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
    Gründker C; Wokoun U; Hellriegel M; Emons G
    J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.
    Shahsavari Z; Karami-Tehrani F; Salami S; Ghasemzadeh M
    Tumour Biol; 2016 Apr; 37(4):4479-91. PubMed ID: 26496737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
    Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
    PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
    Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
    J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vivo performance of ferrocenyl tamoxifen lipid nanocapsules in xenografted triple negative breast cancer.
    Lainé AL; Adriaenssens E; Vessières A; Jaouen G; Corbet C; Desruelles E; Pigeon P; Toillon RA; Passirani C
    Biomaterials; 2013 Sep; 34(28):6949-56. PubMed ID: 23777919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.